Basal cell carcinoma natural history: Difference between revisions

Jump to navigation Jump to search
 
(22 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Basal cell carcinoma}}
{{Basal cell carcinoma}}
{{CMG}} {{AE}} Saarah T. Alkhairy, M.D.
{{CMG}} {{AE}}{{M.N}} Saarah T. Alkhairy, M.D.


==Overview==
==Overview==
Basal cell carcinoma is slow-growing and locally invasive. Common complications of BCC commonly include reccurrence and development of other types of skin cancer. Prognosis is usually excellent, but the tumor is usually locally invasive and may be destructive.
It is a slow-growing [[Local|locally]] [[invasive]] [[lesion]] with an unlikely risk of [[metastasis]]. Most [[patients]] are often [[asymptomatic]]. The major [[complication]] is its recurrence and involvement of surrounding structures. With appropriate treatment, the [[prognosis]] is usually excellent.


==Natural History==
==Natural History==
*Patients with basal cell carcinoma are often asymptomatic
*[[Patients]] with basal cell carcinoma are often [[asymptomatic]]<ref name="pmid14525881">{{cite journal |vauthors=Wong CS, Strange RC, Lear JT |title=Basal cell carcinoma |journal=BMJ |volume=327 |issue=7418 |pages=794–8 |date=October 2003 |pmid=14525881 |pmc=214105 |doi=10.1136/bmj.327.7418.794 |url=}}</ref>
*Basal cell carcinoma is slow-growing and locally invasive
*They often report a slowly enlarging [[lesion]] which does not [[Healing|heal]] and [[Bleed|bleeds]] when [[Trauma|traumatized]]
*It is [[Local|locally]] [[invasive]] and destructive so the name [[Rodent ulcer|'''rodent cancer''']]
*The overall risk of [[metastases]] is estimated to be less than 0.1%
*The overall risk of [[metastases]] is estimated to be less than 0.1%
*The risk of invasion and recurrence is based on size, duration, location and subtype (sclerodermiform/morpheaform and micronodular clinical variants have a higher risk)
*The risk of [[invasion]] and recurrence is based on size, duration, [[Location parameter|location]] and subtype (sclerodermiform/morpheaform and micronodular [[clinical]] variants have a higher risk)
*Even without a recurrence, a personal history of basal cell carcinoma increases the risk of developing all types of skin cancers
*Even without a recurrence, a [[Personal, Social and Health Education|personal]] [[History and Physical examination|history]] of basal cell carcinoma increases the risk of [[Development|developing]] all types of [[skin cancers]]


==Complications==
==Complications==
Complications of basal cell carcinoma are the following:
*The main [[complication]] of basal cell carcinoma is recurrence.<ref name="WortsmanVergara2015">{{cite journal|last1=Wortsman|first1=X.|last2=Vergara|first2=P.|last3=Castro|first3=A.|last4=Saavedra|first4=D.|last5=Bobadilla|first5=F.|last6=Sazunic|first6=I.|last7=Zemelman|first7=V.|last8=Wortsman|first8=J.|title=Ultrasound as predictor of histologic subtypes linked to recurrence in basal cell carcinoma of the skin|journal=Journal of the European Academy of Dermatology and Venereology|volume=29|issue=4|year=2015|pages=702–707|issn=09269959|doi=10.1111/jdv.12660}}</ref><ref name="pmid22560426">{{cite journal |vauthors=Jebodhsingh KN, Calafati J, Farrokhyar F, Harvey JT |title=Recurrence rates of basal cell carcinoma of the periocular skin: what to do with patients who have positive margins after resection |journal=Can. J. Ophthalmol. |volume=47 |issue=2 |pages=181–4 |date=April 2012 |pmid=22560426 |doi=10.1016/j.jcjo.2012.01.024 |url=}}</ref>
*Reccurrence
*The following are the factors associated with increased risk of basal cell carcinoma recurrence:
*Development of other types of skin cancer
**[[Location parameter|Location]] and size
*[[Metastasis]]
***>/= 6 mm in [[diameter]] in high-risk areas (eg, central [[face]], [[nose]], [[lips]], [[eyelids]], [[eyebrows]], periorbital [[skin]], [[chin]], [[mandible]], [[ears]], preauricular and postauricular areas, [[temples]], [[hands]], [[feet]])
*Jaw [[cysts]] (90% by 40 years)<ref name="EvansLadusans1993">{{cite journal|last1=Evans|first1=D G|last2=Ladusans|first2=E J|last3=Rimmer|first3=S|last4=Burnell|first4=L D|last5=Thakker|first5=N|last6=Farndon|first6=P A|title=Complications of the naevoid basal cell carcinoma syndrome: results of a population based study.|journal=Journal of Medical Genetics|volume=30|issue=6|year=1993|pages=460–464|issn=1468-6244|doi=10.1136/jmg.30.6.460}}</ref>
***10 mm in [[diameter]] in other areas of the [[head]] and [[neck]]
*[[Ovarian]] [[calcification]] or [[fibroma]] (24%)<ref name="EvansLadusans1993">{{cite journal|last1=Evans|first1=D G|last2=Ladusans|first2=E J|last3=Rimmer|first3=S|last4=Burnell|first4=L D|last5=Thakker|first5=N|last6=Farndon|first6=P A|title=Complications of the naevoid basal cell carcinoma syndrome: results of a population based study.|journal=Journal of Medical Genetics|volume=30|issue=6|year=1993|pages=460–464|issn=1468-6244|doi=10.1136/jmg.30.6.460}}</ref>  
***20 mm in [[diameter]] in all other areas (excluding [[hands]] and [[feet]])
*[[Medulloblastoma]] (5%)<ref name="EvansLadusans1993">{{cite journal|last1=Evans|first1=D G|last2=Ladusans|first2=E J|last3=Rimmer|first3=S|last4=Burnell|first4=L D|last5=Thakker|first5=N|last6=Farndon|first6=P A|title=Complications of the naevoid basal cell carcinoma syndrome: results of a population based study.|journal=Journal of Medical Genetics|volume=30|issue=6|year=1993|pages=460–464|issn=1468-6244|doi=10.1136/jmg.30.6.460}}</ref>  
**Aggressive [[Pathological|pathologic]] variants
*Cardiac [[fibroma]] (3%)<ref name="EvansLadusans1993">{{cite journal|last1=Evans|first1=D G|last2=Ladusans|first2=E J|last3=Rimmer|first3=S|last4=Burnell|first4=L D|last5=Thakker|first5=N|last6=Farndon|first6=P A|title=Complications of the naevoid basal cell carcinoma syndrome: results of a population based study.|journal=Journal of Medical Genetics|volume=30|issue=6|year=1993|pages=460–464|issn=1468-6244|doi=10.1136/jmg.30.6.460}}</ref>
***Morpheaform, sclerosing, or mixed infiltrative
*[[Cleft palate]] (5%)<ref name="EvansLadusans1993">{{cite journal|last1=Evans|first1=D G|last2=Ladusans|first2=E J|last3=Rimmer|first3=S|last4=Burnell|first4=L D|last5=Thakker|first5=N|last6=Farndon|first6=P A|title=Complications of the naevoid basal cell carcinoma syndrome: results of a population based study.|journal=Journal of Medical Genetics|volume=30|issue=6|year=1993|pages=460–464|issn=1468-6244|doi=10.1136/jmg.30.6.460}}</ref>
***Micronodular
*Ophthalmic complications, such as squint or [[cataracts]] (26%)<ref name="EvansLadusans1993">{{cite journal|last1=Evans|first1=D G|last2=Ladusans|first2=E J|last3=Rimmer|first3=S|last4=Burnell|first4=L D|last5=Thakker|first5=N|last6=Farndon|first6=P A|title=Complications of the naevoid basal cell carcinoma syndrome: results of a population based study.|journal=Journal of Medical Genetics|volume=30|issue=6|year=1993|pages=460–464|issn=1468-6244|doi=10.1136/jmg.30.6.460}}</ref>
***Basosquamous
**[[Lesions]] in sites of prior [[radiation therapy]] (RT)
**[[Lesions]] with poorly defined borders
**[[Lesions]] in [[immunocompromised]] [[patients]]
**Perineural [[invasion]]


==Prognosis==
==Prognosis==
*Prognosis of basal cell carcinoma is usually excellent.
*[[Prognosis]] of basal cell carcinoma is usually excellent.<ref name="Czarnecki1998">{{cite journal|last1=Czarnecki|first1=D.|title=The prognosis of patients with basal and squamous cell carcinoma of the skin|journal=International Journal of Dermatology|volume=37|issue=9|year=1998|pages=656–658|issn=00119059|doi=10.1046/j.1365-4362.1998.00559.x}}</ref><ref name="pmid26449265">{{cite journal |vauthors=Correia de Sá TR, Silva R, Lopes JM |title=Basal cell carcinoma of the skin (part 2): diagnosis, prognosis and management |journal=Future Oncol |volume=11 |issue=22 |pages=3023–38 |date=November 2015 |pmid=26449265 |doi=10.2217/fon.15.245 |url=}}</ref>
*These lesions are typically slow growing, and metastatic disease is a very rare event.  
*These [[lesions]] are typically slow growing, and [[metastatic]] [[disease]] is a very [[rare]] event.  
*BCCs will cause considerable disfigurement by locally destroying skin, cartilage, and even bone.
*Basal cell carcinoma will cause considerable [[disfigurement]] by [[Local|locally]] destroying [[skin]], [[cartilage]], and even [[bone]].
*Recurrence is a issue with basal cell carcinoma.
*Recurrence is a issue with basal cell carcinoma.
*Approximately 50% of recurrences are apparent within the first two years.
*Approximately 50% of recurrences are apparent within the first two years.
Line 35: Line 40:
{{reflist|2}}
{{reflist|2}}


[[Category:Disease]]
[[Category:Dermatology]]
[[Category:Types of cancer]]
[[Category:Pathology]]


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Medicine]]
[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Surgery]]
[[Category:Surgery]]

Latest revision as of 14:36, 11 March 2019

Basal cell carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Basal Cell Carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

CT scan

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Basal cell carcinoma natural history On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Basal cell carcinoma natural history

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Basal cell carcinoma natural history

CDC on Basal cell carcinoma natural history

Basal cell carcinoma natural history in the news

Blogs on Basal cell carcinoma natural history

Directions to Hospitals Treating Basal cell carcinoma

Risk calculators and risk factors for Basal cell carcinoma natural history

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maneesha Nandimandalam, M.B.B.S.[2] Saarah T. Alkhairy, M.D.

Overview

It is a slow-growing locally invasive lesion with an unlikely risk of metastasis. Most patients are often asymptomatic. The major complication is its recurrence and involvement of surrounding structures. With appropriate treatment, the prognosis is usually excellent.

Natural History

Complications

Prognosis

References

  1. Wong CS, Strange RC, Lear JT (October 2003). "Basal cell carcinoma". BMJ. 327 (7418): 794–8. doi:10.1136/bmj.327.7418.794. PMC 214105. PMID 14525881.
  2. Wortsman, X.; Vergara, P.; Castro, A.; Saavedra, D.; Bobadilla, F.; Sazunic, I.; Zemelman, V.; Wortsman, J. (2015). "Ultrasound as predictor of histologic subtypes linked to recurrence in basal cell carcinoma of the skin". Journal of the European Academy of Dermatology and Venereology. 29 (4): 702–707. doi:10.1111/jdv.12660. ISSN 0926-9959.
  3. Jebodhsingh KN, Calafati J, Farrokhyar F, Harvey JT (April 2012). "Recurrence rates of basal cell carcinoma of the periocular skin: what to do with patients who have positive margins after resection". Can. J. Ophthalmol. 47 (2): 181–4. doi:10.1016/j.jcjo.2012.01.024. PMID 22560426.
  4. Czarnecki, D. (1998). "The prognosis of patients with basal and squamous cell carcinoma of the skin". International Journal of Dermatology. 37 (9): 656–658. doi:10.1046/j.1365-4362.1998.00559.x. ISSN 0011-9059.
  5. Correia de Sá TR, Silva R, Lopes JM (November 2015). "Basal cell carcinoma of the skin (part 2): diagnosis, prognosis and management". Future Oncol. 11 (22): 3023–38. doi:10.2217/fon.15.245. PMID 26449265.


Template:WikiDoc Sources